MCID: NRV006
MIFTS: 47

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15 17
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 70
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 70
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 44
Nervous System--Cancer 70
Nervous System Tumor 54
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 34 192.9
MeSH 44 D009380
NCIt 50 C35562
SNOMED-CT 67 188306000
UMLS 70 C0027665 C0027766 C0153643 more

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to central nervous system cancer and autonomic nervous system neoplasm. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Temozolomide and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include nervous system, brain and bone, and related phenotype is neoplasm.

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 central nervous system cancer 33.3 U2AF1 NF2 NF1 MIR9-1 MIR34A MIR21
2 autonomic nervous system neoplasm 33.3 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
3 brain cancer 32.5 NF2 NF1 MIR9-1 KDM4C H2AC18 GLIPR1
4 central nervous system hematologic cancer 32.5 MIR199A1 MIR124-1 KDM4C
5 meningioma, familial 32.4 NF2 NF1 MIR34A H2AC18 CDKN2B
6 peripheral nervous system neoplasm 32.4 U2AF1 NF2 NF1 MIR9-1 MIR34A MIR21
7 anaplastic astrocytoma 31.0 MIR196A1 KDM4C H2AC18 CDKN2B
8 medulloblastoma 30.9 NF1 MIR9-1 MIR34A MIR17 MIR125A MIR124-1
9 neuroblastoma 30.8 NF1 MIR34A MIR21 MIR17 MIR125A CASP3
10 high grade glioma 30.8 NF1 MIR196A1 CDKN2B-AS1 CDKN2B CASP3
11 demyelinating disease 30.7 U2AF1 MIR9-1 MIR155 MIR125A MIR124-1 H2AC18
12 glioma 30.7 NF1 MIR34A MIR21 MIR17 GLIPR1 CDKN2B-AS1
13 diffuse astrocytoma 30.7 NF1 KDM4C H2AC18
14 lymphoma, hodgkin, classic 30.7 MIR21 MIR155 KDM4C BCL2
15 glioblastoma 30.7 NF1 MIR34A MIR21 MIR155 GLIPR1 CDKN2B
16 malignant astrocytoma 30.6 U2AF1 NF1 MIR9-1 MIR199A1 MIR196A1 MIR17
17 rhabdoid cancer 30.6 NF2 KDM4C H2AC18
18 pancreatic cancer 30.6 MIR34A MIR21 MIR199A1 MIR196A1 MIR17 MIR155
19 lymphoma, non-hodgkin, familial 30.6 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
20 brain glioma 30.6 NF1 MIR34A KDM4C
21 plexiform schwannoma 30.4 NF2 NF1
22 olfactory neural tumor 11.2
23 inherited nervous system cancer-predisposing syndrome 11.2
24 rare nervous system tumor 11.2
25 lipofibromatosis-like neural tumor 11.1
26 ectomesenchymoma 11.1
27 subependymal giant cell astrocytoma 11.0
28 central nervous system primitive neuroectodermal neoplasm 11.0
29 central nervous system sarcoma 11.0
30 cranial nerve neoplasm 11.0
31 central nervous system germ cell tumor 11.0
32 central nervous system melanocytic neoplasm 11.0
33 central nervous system mesenchymal non-meningothelial tumor 11.0
34 spinal cancer 11.0
35 melanoma-astrocytoma syndrome 10.9
36 central nervous system benign neoplasm 10.6 NF2 NF1 MIR34A KDM4C H2AC18
37 cerebral arterial disease 10.6 NF1 MIR199A1 MIR125A CDKN2B-AS1 CDKN2B
38 fetal alcohol spectrum disorder 10.6 MIR9-1 KDM4C H2AC18 CASP3
39 fetal alcohol syndrome 10.6 MIR9-1 KDM4C H2AC18 CASP3
40 bone sarcoma 10.6 MIR9-1 MIR21 MIR199A1 MIR17 KDM4C H2AC18
41 oropharynx cancer 10.6 MIR9-1 MIR199A1 H2AC18 CASP3 APC
42 retinal vascular disease 10.6 MIR21 MIR199A1 MIR17 H2AC18 CASP3
43 muscle cancer 10.6 NF1 MIR9-1 MIR199A1 MIR196A1 H2AC18
44 brain stem cancer 10.6 NF1 KDM4C H2AC18
45 endocrine organ benign neoplasm 10.6 NF1 MIR21 MIR199A1 KDM4C H2AC18
46 pleural disease 10.6 NF2 MIR199A1 MIR17 MIR125A MIR124-1 H2AC18
47 primary mediastinal b-cell lymphoma 10.6 MIR9-1 MIR155 KDM4C BCL2
48 skin melanoma 10.6 U2AF1 NF1 MIR199A1 KDM4C H2AC18 CDKN2B
49 infratentorial cancer 10.6 U2AF1 NF1 MIR9-1 MIR199A1 MIR196A1 MIR17
50 cardiovascular organ benign neoplasm 10.6 NF1 KDM4C H2AC18 APC

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

MGI Mouse Phenotypes related to Nervous System Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC BCL2 CDKN2B GLIPR1 KDM4C NF1

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 409)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 4 85622-93-1 5394
2
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
3 Orange Approved Phase 3
4
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
7
Trioxsalen Approved Phase 3 3902-71-4 5585
8
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
9
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
10
Ofloxacin Approved Phase 3 82419-36-1 4583
11
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
12
Thioguanine Approved Phase 3 154-42-7 2723601
13
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
14
Gemcitabine Approved Phase 3 95058-81-4 60750
15
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
20
Molgramostim Investigational Phase 3 99283-10-0
21
Mitolactol Investigational Phase 3 10318-26-0
22 Clavulanic Acids Phase 3
23 Amoxicillin-Potassium Clavulanate Combination Phase 3
24 beta-Lactamase Inhibitors Phase 3
25 Photosensitizing Agents Phase 3
26 Antiemetics Phase 3
27 Emetics Phase 3
28 Liver Extracts Phase 3
29 Anesthetics, General Phase 3
30 Anesthetics Phase 3
31 Dihematoporphyrin Ether Phase 3
32 Cytochrome P-450 Enzyme Inhibitors Phase 3
33 Ether Phase 3
34 Anesthetics, Inhalation Phase 3
35 Hematoporphyrins Phase 3
36 Hematoporphyrin Derivative Phase 3
37 Anti-Infective Agents Phase 3
38 Antimetabolites Phase 3
39 Vitamin B9 Phase 3
40 Vitamin B Complex Phase 3
41 Folic Acid Antagonists Phase 3
42 Folate Phase 3
43 Antiviral Agents Phase 3
44 Neurotransmitter Agents Phase 3
45 Dopamine Agents Phase 3
46 Central Nervous System Stimulants Phase 3
47 Dopamine Uptake Inhibitors Phase 3
48 Dexmethylphenidate Hydrochloride Phase 3
49
Nedaplatin Approved, Investigational Phase 2 95734-82-0
50
Ranitidine Approved, Withdrawn Phase 1, Phase 2 66357-59-3, 66357-35-5, 82530-72-1 3001055

Interventional clinical trials:

(show top 50) (show all 621)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
3 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
7 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
8 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
10 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
13 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
14 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
15 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
16 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
17 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
18 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
19 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
20 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
21 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
22 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
23 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
24 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
25 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
26 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
27 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
28 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
29 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
30 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
31 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
32 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
33 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
34 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
35 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
36 A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care for First Line Treatment of RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer Recruiting NCT04222972 Phase 3 Pralsetinib;Carboplatin;Cisplatin;Pemetrexed;Pembrolizumab;Gemcitabine
37 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
38 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
39 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
40 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
41 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
42 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
43 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
44 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
45 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
46 Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
47 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
48 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
49 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
50 A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas Unknown status NCT00514397 Phase 2 motexafin gadolinium;temozolomide

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

19
Nervous System

MalaCards organs/tissues related to Nervous System Cancer:

40
Brain, Bone, Skin, Prostate, Pituitary, Bone Marrow, Spinal Cord

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show top 50) (show all 228)
# Title Authors PMID Year
1
Validated quantitative needs assessment differences in the management of children with central nervous system cancer between Brazil, an upper middle-income country, and the United States of America, a high income country. 61
33760367 2021
2
Optimizing ANFIS using simulated annealing algorithm for classification of microarray gene expression cancer data. 61
33543413 2021
3
Work Personality, Core Self-evaluation and Perceived Career Barriers in Young Adult Central Nervous System Cancer Survivors. 61
32399851 2021
4
Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier. 61
33326131 2021
5
Proteogenomic and metabolomic characterization of human glioblastoma. 61
33577785 2021
6
Potential Drug Prediction of Glioblastoma Based on Drug Perturbation-Induced Gene Expression Signatures. 61
33575336 2021
7
Case report of pulmonary metastasis in a male Wistar rat glioblastoma model. 61
33627949 2021
8
Comparing the ICD-11 chronic pain classification with ICD-10: how can the new coding system make chronic pain visible? A study in a tertiary care pain clinic setting. 61
33449507 2021
9
Computational Modeling of Neuropsychological Test Performance to Disentangle Impaired Cognitive Processes in Cancer Patients. 61
32239149 2021
10
Impact of non-CNS childhood cancer on resting-state connectivity and its association with cognition. 61
33205895 2021
11
Expression Profile Analysis Identifies a Novel Seven Immune-Related Gene Signature to Improve Prognosis Prediction of Glioblastoma. 61
33708242 2021
12
Evaluation of the lifetime brain/central nervous system cancer risk associated with childhood head CT scanning in Japan. 61
33320957 2020
13
High incidence of brain and other nervous system cancer identified in two mining counties, 2001-2015: insufficient evidence to support association with heavy metal exposure. 61
33138950 2020
14
Chemotherapy-induced grey matter abnormalities in cancer survivors: a voxel-wise neuroimaging meta-analysis. 61
33047236 2020
15
Gene regulation network analysis reveals core genes associated with survival in glioblastoma multiforme. 61
32696617 2020
16
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. 61
32998735 2020
17
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. 61
32459291 2020
18
Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art. 61
32867643 2020
19
Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. 61
32146576 2020
20
Multiclass magnetic resonance imaging brain tumor classification using artificial intelligence paradigm. 61
32658726 2020
21
Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. 61
31630356 2020
22
Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. 61
32129445 2020
23
Genetic epidemiology of colorectal cancer and associated cancers. 61
31424514 2020
24
Toxicity of Saffron Extracts on Cancer and Normal Cells: A Review Article. 61
32711409 2020
25
Locoregionally Delivered CAR T Cells Are Effective in CNS Cancer Models. 61
32385074 2020
26
Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial. 61
32690067 2020
27
Neurological diseases in Peru: a systematic analysis of the global burden disease study. 61
32490965 2020
28
Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study. 61
31498410 2020
29
Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. 61
32004776 2020
30
Case-control study of brain and other central nervous system cancer among workers at semiconductor and storage device manufacturing facilities. 61
32019845 2020
31
Amentoflavone suppresses cell proliferation and induces cell death through triggering autophagy-dependent ferroptosis in human glioma. 61
32057904 2020
32
Donors With Central Nervous System Cancer: Proceed With Vigilance. 61
31596741 2020
33
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. 61
32124043 2020
34
Spinal Clear Cell Meningiomas: Clinical Features and Factors Predicting Recurrence. 61
31765868 2020
35
Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion. 61
32102688 2020
36
High incidence of brain and other nervous system cancer identified in two mining counties, 2001-2015. 61
32007285 2020
37
Epidemiology of cancer in Saudi Arabia thru 2010-2019: a systematic review with constrained meta-analysis. 61
32968686 2020
38
Glioma stages prediction based on machine learning algorithm combined with protein-protein interaction networks. 61
31150762 2020
39
Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study. 61
33395962 2020
40
Cancer incidence and mortality trends in young adults in Metropolitan Lima young adults, 1990-2012. 61
32346391 2020
41
Distinguishing Glioblastoma Subtypes by Methylation Signatures. 61
33329750 2020
42
Risk of Being Born Preterm in Offspring of Cancer Survivors: A National Cohort Study. 61
32850432 2020
43
Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition. 61
33293793 2020
44
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancer. 61
31553925 2019
45
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 61
30585513 2019
46
PD-L1/PD-1 Axis in Glioblastoma Multiforme. 61
31661771 2019
47
Bimodular Antiparallel G-Quadruplex Nanoconstruct with Antiproliferative Activity. 61
31597343 2019
48
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 61
31049790 2019
49
Age, cancer site and gender associations with symptoms and problems in specialised palliative care: a large, nationwide, register-based study. 61
31563863 2019
50
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 61
30395335 2019

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR155
2 11.53 MIR9-1 MIR21 MIR125A MIR124-1 CASP3
3 11.4 CDKN2B CASP3 BCL2
4 10.99 CDKN2B CASP3 BCL2

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 8.92 MIR34A MIR21 MIR17 MIR125A

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10 MIR34A MIR21 MIR155 MIR125A KDM4C CDKN2B-AS1
2 negative regulation of cell proliferation GO:0008285 9.91 NF2 NF1 MIR9-1 MIR21 CDKN2B BCL2
3 negative regulation of angiogenesis GO:0016525 9.86 NF1 MIR34A MIR21 MIR125A
4 regulation of protein stability GO:0031647 9.8 NF2 CASP3 BCL2
5 cellular response to hypoxia GO:0071456 9.8 MIR34A MIR17 MIR155 MIR124-1 BCL2
6 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 MIR21 CDKN2B BCL2 APC
7 positive regulation of cell death GO:0010942 9.75 MIR34A MIR155 APC
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.74 MIR199A1 MIR196A1 MIR155
9 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.72 CDKN2B CASP3 APC
10 miRNA mediated inhibition of translation GO:0035278 9.72 MIR9-1 MIR21 MIR17 MIR155 MIR124-1
11 negative regulation of MAPK cascade GO:0043409 9.71 NF2 NF1 MIR21
12 negative regulation of gene expression GO:0010629 9.7 MIR34A MIR21 MIR17 MIR155 MIR125A MIR124-1
13 negative regulation of JAK-STAT cascade GO:0046426 9.69 NF2 MIR9-1 MIR155
14 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR199A1 MIR17 MIR155
15 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.64 MIR17 MIR155
16 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.64 MIR21 MIR125A
17 regulation of cell-matrix adhesion GO:0001952 9.63 NF1 BCL2
18 positive regulation of connective tissue replacement GO:1905205 9.63 MIR34A MIR199A1 MIR155
19 negative regulation of microglial cell activation GO:1903979 9.62 MIR155 MIR124-1
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.62 MIR155 MIR125A
21 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
22 negative regulation of vascular wound healing GO:0061044 9.61 MIR34A MIR155
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR199A1 MIR17 MIR155
24 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.6 MIR21 MIR124-1
25 negative regulation of regulatory T cell differentiation GO:0045590 9.59 MIR21 MIR155
26 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR21 MIR17
27 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR199A1 MIR17 MIR125A
28 negative regulation of cell migration GO:0030336 9.43 NF2 NF1 MIR9-1 MIR34A MIR21 BCL2
29 gene silencing by miRNA GO:0035195 9.28 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR9-1 MIR34A MIR21 MIR17 MIR125A MIR124-1
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN2B CASP3

Sources for Nervous System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....